BioNTech SE (BNTX.xnas)

traders view logo Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

BioNTech SE (BNTX.xnas) Profile

BioNTech SE (BNTX.xnas) is a biotechnology company developing and commercialising immunotherapies for cancer and other infectious diseases headquartered in Mainz, Germany. BioNTech develops pharmaceutical product candidates for advanced melanoma, prostate cancer, triple-negative breast cancer, ovarian cancer, cell lung cancer and neoantigen-specific immunotherapies, such as Autogene cevumeran. BioNTech along with Pfizer, developed the RNA vaccine BNT 162b2 to prevent COVID-19 infections, the first mRNA vaccine ever authorized and approved later in the United States, Canada, and Switzerland. BioNTech operates in Germany, San Diego, Cambridge, and Massachusetts, with 8 offices in 2 countries. The company employs 1323 people and has a market capitalisation of $73.41B (USD) as of December 2021. BioNTech stock (BNTX.xnas) is listed as American Depository Shares (ADS) on the NASDAQ Global Select Market. BioNTech plans to open its Asia headquarters in Singapore and a vaccine manufacturing plant with support from the Singapore Economic Development Board in 2023. BioNTech aim to produce hundreds of millions of doses of mRNA vaccines per year. In November 2021, BioNTech and Pfizer announced that a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant, and they could deliver an Omicron-based vaccine in March 2022 if needed.

Holding cost
Trading hours in US Eastern Time

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

Why Trade BioNTech SE (BNTX.xnas) with FP Markets? An Australian-regulated forex & CFD broker
go long or short
Go Long or Short

Increase your ability to profit in
all market conditions
Leverage options up to 20:1

direct market access
Direct Market Access (DMA) Execution

Real-time, transparent share prices
Control, Functionality and deep liquidity
Full Market depth & see your orders in the queue

advanced platforms
Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with
superior client portal

24/5 Multilingual customer support
24/5 Multilingual
Customer Support

Award winning support &
personal account managers

global exposure
Global Exposure

Low margins and competitive commission
+10,000 products on global stocks
across 4 continents

earn dividends
Earn Dividends

On long positions
No ownership of physical
shares necessary

거래 시작

bullet 10,000여 금융상품 거래 가능
bullet 자동으로 포지션 개시 및 종료
bullet 뉴스 및 경제 캘린더
bullet 보조지표 및 차트
bullet 기타 여러 도구 포함

고객님께서 이메일을 제공해주신다는 것은 FP Markets 개인 정보 정책에 동의함과 동시에 마케팅자료를 받아 보신다는 것을 의미합니다. 언제든지 구독취소가 가능합니다.

Source - cache | Page ID - 13649

Get instant Updates in Telegram